Universal Technical Institute

UTI · NYSE

$20.59−$0.22 (−1.06%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $20.81

UTI analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $37.59 (+82.6% upside)

Low: $25.25
Now: $20.59
High: $50.40

Upgrades and downgrades

The latest rating actions, newest first

UTI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Aug 6, 2026	Maintains	Buy	$47.00 → $38.00	63%
B. Riley Securities	Aug 6, 2026	Maintains	Buy	$49.00 → $48.00	40%
Rosenblatt	Aug 6, 2026	Maintains	Buy	$45.00	57%
Truist Securities	Jun 29, 2026	Maintains	Buy	$40.00 → $47.00	63%
Barrington Research	May 7, 2026	Maintains	Outperform	$36.00 → $42.00	63%
Rosenblatt	May 7, 2026	Maintains	Buy	$36.00 → $45.00	57%
Barrington Research	Apr 17, 2026	Maintains	Outperform	$36.00	63%
Barrington Research	Feb 5, 2026	Maintains	Outperform	$36.00	63%
Rosenblatt	Feb 5, 2026	Maintains	Buy	$36.00	57%
Barrington Research	Jan 21, 2026	Maintains	Outperform	$36.00	63%

The case for and against

Updated Oct 14, 2026

Bull case

Universal Technical is supported by resilient demand for skilled-trades and healthcare training, with new student starts rising 10.9% in the quarter and 3Q starts up 23% year over year at UTI, while Concorde’s revenue grew 11% year over year to $80.9 million. The company is also showing operational leverage in a high-fixed-cost model, as it expands campus capacity with Atlanta and San Antonio tracking ahead of plan and expects over $1.2 billion of revenue and about $220 million of adjusted EBITDA in FY29. Near-term investment is pressuring margins and free cash flow, but with cash of $170 million, demand still outstripping supply, and multiple growth catalysts in new campuses, programs, and employer partnerships, the fundamentals remain compelling.

Bear case

Universal Technical is facing a deteriorating near-term enrollment mix and execution risk, as High School starts in the September quarter are roughly 1,000 below plan despite leads rising 15%, implying weak conversion from a turnover-hit recruiting team. Management’s response has forced lower guidance, cutting full-year revenue to $893 million-$900 million from $905 million-$915 million, EBITDA to $100 million-$103 million from $114 million-$119 million, and free cash flow to ($20 million) to breakeven amid higher CapEx. Although Q2/26 revenue rose 6.7% to $221.4 million and starts increased 13.8%, EBITDA margin fell to 6.4% and operating income nearly disappeared, underscoring a high fixed-cost model and heavy ongoing growth spending.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.